Archives: 2026-11-11

Loberamisal improves functional recovery after an ischemic stroke

A new neuroprotective and neuroreparative treatment could expand therapeutic options after an acute ischemic stroke. The LAIS clinical trial has demonstrated that intravenous loberamisal, administered within the first ten days and initiated within 48 hours of symptom onset, significantly increases the proportion of patients achieving full functional recovery at 90 days. The results of the

Read More


FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Non-arteritic Ischemic Optic Neuropathy (NAION) a Rare But Serious Eye Condition

The FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss. What is FDA

Read More


Researchers at Michigan Medicine have uncovered that sotagliflozin, an FDA-approved diabetes medication, reduces the risk of heart attack and stroke.

New study uncovers why sotagliflozin may lower risk of heart attack and stroke For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health.  Researchers at Michigan Medicine have uncovered a mechanism that may explain why sotagliflozin, an FDA-approved diabetes medication marketed as Inpefa, reduces the risk of

Read More


University of California San Francisco researchers have engineered smarter CAR-T Cells that Could Beat a Deadly Pediatric Brain Cancer

A UCSF team engineered immune cells to activate exclusively in the brain and attack diffuse midline glioma. It worked in mice and it’s poised for a clinical trial at UCSF. Scientists at UC San Francisco have engineered CAR-T cells that stay dormant until they reach the brain, where they switch on and destroy tumor cells.

Read More


New mRNA personalised therapeutic cancer vaccine cuts 42% risk of melanoma recurrence, opening door to new era of cancer treatment.

In a world-first international trial, adding a therapeutic cancer vaccine to standard immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%. Trial findings herald a foundational shift in how cancer is treated. Proven in melanoma, these results establish a new personalised approach, opening the door for potential new treatments

Read More


Young adults with Coronary Artery Calcium above the 90th percentile face markedly increased long-term risk of cardiovascular disease and coronary heart disease mortality

In a cohort study, published in JAMA Cardiology, including 12 847 participants, those aged 30 to 45 years with CAC above the 90th percentile had statistically significantly higher modeled 30-year mortality risks than those without CAC. Key PointsWhat are the long-term implications of having elevated coronary artery calcium (CAC) scores in young adults compared with their

Read More


Half-Matched Bone Marrow Transplant Expands Treatment Options for Children and Young Adults with Severe Aplastic Anemia

Researchers at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins Children’s Center report that bone marrow transplant using half-matched family donors achieved a 96% survival rate among children, adolescent, and young adult patients with severe aplastic anemia, a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood

Read More


Exercise Prescriptions for Cardiovascular Health in Adults: 2026 American College of Cardiology Scientific Statement

Exercise should be prescribed as a foundational component of cardiovascular disease (CVD) prevention and treatment, according to a new American College of Cardiology scientific statement published in JACC. The statement emphasizes that the greatest reduction in cardiovascular risk occurs when sedentary individuals become even modestly more active, and the best exercise prescription is one that

Read More


New international consensus updates framework for CAR T-cell therapy in severe autoimmune diseases

Experts from EBMT, ISCT and JACIE, with representatives from EULAR and ECTRIMS, have published updated recommendations supporting careful patient selection, multidisciplinary care and long-term follow-up as CAR T-cell therapy expands beyond cancer. An international multidisciplinary group of 31 experts has updated consensus recommendations for using chimeric antigen receptor (CAR) T-cell therapy in people with severe,

Read More